At Biogen, our mission is clear: we are pioneers in neuroscience. Biogen discovers, develops, and delivers worldwide innovative therapies for people living with serious neurological and neurodegenerative diseases as well as related therapeutic adjacencies. One of the world’s first global biotechnology companies, Biogen was founded in 1978 by Charles Weissmann, Heinz Schaller, Kenneth Murray, and Nobel Prize winners Walter Gilbert and Phillip Sharp. Today, Biogen has the leading portfolio of medicines to treat multiple sclerosis (MS), has introduced the first approved treatment for spinal muscular atrophy, commercialises biosimilars of advanced biologics, and is focused on advancing research programmes in MS and neuroimmunology, neuromuscular disorders, movement disorders, Alzheimer’s disease and dementia, ophthalmology, immunology, neurocognitive disorders, acute neurology, and pain. To learn more, please visit: www.biogen.uk.com.
|Life Molecular Imaging|
|Alzheimer's Research UK
Alzheimer’s Research UK is the UK’s leading dementia research charity dedicated to diagnosis, prevention, treatment and cure. Backed by our passionate scientists and supporters, we’re challenging the way people think about dementia, bringing together the people and organisations who can speed up progress, and investing in research to make life-changing breakthroughs possible.
Our research work focuses on four areas: understanding dementia, improving diagnosis, reducing risk and developing treatments. Our mission is to bring about the first life-changing dementia treatment by 2025. To date we have funded over £151 million of ground-breaking research into all the most common types of dementia.
As well as funding and delivering pioneering research, we collaborate with others to speed up global scientific progress, and we work to confront misconceptions across society.
An important part of our work is producing high-quality health information on dementia and the diseases that cause it. These include booklets about the diseases that cause dementia, treatments available, genes and dementia, and reducing your risk. All our health information is accredited by the Patient Information Forum PIF TICK scheme and is free to order from our website or by telephone.
Alzheimer’s Research UK is proud to be one of the founding partners in Join Dementia Research, a service for the public to register to take part in dementia research. The charity’s Dementia Research Infoline provides a helpline service (0300 111 5 111 firstname.lastname@example.org) for people wanting more information about dementia, dementia research and taking part in research.